➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School

Last Updated: June 18, 2021

DrugPatentWatch Database Preview


Email this page to a colleague

« Back to Dashboard

When do Moxidectin patents expire, and what generic alternatives are available?

Moxidectin is a drug marketed by Mdgh and is included in one NDA.

The generic ingredient in MOXIDECTIN is moxidectin. There is one drug master file entry for this compound. Additional details are available on the moxidectin profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Moxidectin

A generic version of MOXIDECTIN was approved as moxidectin by MDGH on June 13th, 2018.

  Try Before You Buy

Summary for MOXIDECTIN
US Patents:0
Raw Ingredient (Bulk) Api Vendors: 46
Clinical Trials: 19
Patent Applications: 3,115
Formulation / Manufacturing:see details
What excipients (inactive ingredients) are in MOXIDECTIN?MOXIDECTIN excipients list
DailyMed Link:MOXIDECTIN at DailyMed
Drug patent expirations by year for MOXIDECTIN
Recent Clinical Trials for MOXIDECTIN

Identify potential brand extensions & 505(b)(2) entrants

Jennifer KeiserPhase 2/Phase 3
Public Health Laboratory Ivo de Carneri, Chake Chake, Pemba, Zanzibar, TanzaniaPhase 2/Phase 3
National Centre for Parasitology, Entomology and Malaria Control, CambodiaPhase 3

See all MOXIDECTIN clinical trials

US Patents and Regulatory Information for MOXIDECTIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mdgh MOXIDECTIN moxidectin TABLET;ORAL 210867-001 Jun 13, 2018 RX Yes Yes   Try Before You Buy   Try Before You Buy   Try Before You Buy
Mdgh MOXIDECTIN moxidectin TABLET;ORAL 210867-001 Jun 13, 2018 RX Yes Yes   Try Before You Buy   Try Before You Buy   Try Before You Buy
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.